Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Tumor type

Invasive Breast Carcinoma

OncoTree code BRCA · 26 articles

Molecular biology · Bioinfo & AI

Integrative multi-omics profiling and machine learning reveal enhancer RNA signatures for early detection and prognostic stratification in breast cancer

Xia J, Tian J, Cao Y, et al.

NAR cancer

This study investigated the potential of enhancer RNAs (eRNAs) as biomarkers for breast cancer, complementing traditional protein-coding transcripts. By profiling eRNA expression across over 1000 TCGA-BRCA samples and healthy tissues, researchers developed a 10-eRNA signature that effectively stratified patients into high- and low-risk groups, demonstrating independent prognostic value. Furthermore, a 19-eRNA panel was designed for early detection, showing excellent performance on an independent cohort. These tools have been integrated into eRNACare, a publicly accessible web application, highlighting the promising role of eRNAs for breast cancer risk stratification, therapeutic guidance, and early diagnosis.

Clinical · Molecular biology

Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial

Schochter F, Friedl TWP, Schäffler H, et al.

Breast cancer research and treatment

The phase II DETECT IVb trial assessed the efficacy and safety of eribulin in patients with HER2-negative metastatic breast cancer, focusing on circulating tumor cell (CTC) dynamics. The study confirmed eribulin as an effective treatment option for this high-risk population, showing a median progression-free survival of 4.6 months and a median overall survival of 13.4 months. Furthermore, CTC clearance was significantly associated with improved progression-free survival. The observed adverse events were consistent with the known safety profile of eribulin.

Clinical · Molecular biology · Bioinfo & AI

Development and validation of a machine learning clinicogenomic model to improve prognostic stratification in ER-positive/HER2-negative early breast cancer

Sarafidis M, Sifakis EG, Bergh J, et al.

Breast cancer research

A machine learning-based clinicogenomic model has been developed and validated to improve prognostic stratification in ER-positive/HER2-negative early breast cancer. This model integrates a research-grade implementation of the 21-gene recurrence score, a 14-gene immunoglobulin signature, and clinicopathologic features. Validated across four independent datasets totaling 5132 patients, it demonstrated improved discrimination and identified larger low-risk groups compared to the standalone 21-gene recurrence score. Explainability analyses revealed time-dependent feature contributions, highlighting the potential of this integrative approach for more accurate risk assessment.

Clinical · Molecular biology

Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis

Friedl TWP, Fasching PA, Hartkopf AD, et al.

JCO precision oncology

This retrospective study, leveraging the phase III SUCCESS-A trial, assessed the prognostic value of tissue-free circulating tumor DNA (ctDNA) detection in patients with early breast cancer. Plasma samples were analyzed approximately two years after adjuvant chemotherapy in 313 patients. ctDNA detection, observed in 5.8% of patients, was strongly associated with a significantly increased risk of distant recurrence and shorter overall survival. ctDNA was detected a median of 7.9 months before recurrence, showing a sensitivity of 73% and a specificity of 99.6% for distant recurrence. These findings suggest that post-treatment ctDNA can stratify patients at high risk of recurrence.

Clinical · Molecular biology

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial

Jhaveri K, Eli LD, Hurvitz SA, et al.

Clinical cancer research

This SUMMIT basket trial study evaluated the efficacy of neratinib alone or in combination with trastuzumab in patients with HER2-mutant metastatic triple-negative breast cancer (TNBC). Results showed confirmed objective response rates of 40% for neratinib alone and 35.3% for the combination, with median progression-free survival times of 2.89 and 6.24 months, respectively. Circulating tumor DNA (ctDNA) monitoring correlated decreases in HER2 mutation variant allele frequencies with treatment response and identified the emergence of resistance mutations. The neratinib and trastuzumab combination appears to prolong responses compared to neratinib alone, offering a novel approach for biomarker-defined metastatic TNBC.

Clinical

Prognostic factors and outcomes associated with postmastectomy radiation therapy following neoadjuvant chemotherapy and mastectomy for breast cancer: A retrospective cohort study

Kang HJ, Kim M, Kwak YK, et al.

Medicine

This retrospective study investigated prognostic factors and outcomes of postmastectomy radiation therapy (PMRT) following neoadjuvant chemotherapy (NAC) and mastectomy for stage II-III breast cancer. It included 178 patients with a median follow-up of 64 months. The findings indicated that response to NAC, molecular subtype, and pathologic stage are independent predictors of treatment outcomes. PMRT did not offer significant benefits for patients with pathologically node-negative disease (ypN0) but significantly improved locoregional control, progression-free survival, and overall survival in those with residual lymph nodes (ypN1-3). Triple-negative subtype and non-response to NAC were identified as poor prognostic factors.

Clinical · Molecular biology

RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition

Ganesan GS, Moosbrugger ZR, Parker PS, et al.

NAR cancer

This study characterized 33 RAD51C variants identified in breast cancer patients, assessing their ability to perform homologous recombination (HR). Researchers found one HR-deficient variant and five with intermediate HR proficiency. Although these variants exhibited only modestly attenuated HR function, they misregulate replication fork progression and accumulate single-strand DNA gaps. Cells expressing these variants, largely resistant to monotherapy, showed increased sensitivity to a combination of PARP1 inhibitors (Saruparib) and ATR inhibitors (Ceralasertib). These findings suggest that RAD51C variants with partial HR function can lead to profound defects in replicative damage repair, potentially resulting in distinct therapeutic responses.

Clinical · Molecular biology · Bioinfo & AI

Deep Learning-Driven Anticancer Drug Discovery: Emodepside as a Potential Therapeutic Candidate for Triple-Negative Breast Cancer

Xu Y, Dong T, Li B, et al.

Journal of chemical information and modeling

This study developed a deep learning framework to accelerate drug discovery for triple-negative breast cancer (TNBC), an aggressive subtype with limited therapeutic options. The model predicted anticancer efficacy, toxicity, and structural similarities of compounds. By screening over 6,000 compounds, the study identified emodepside as a promising candidate. In vitro and in vivo validations confirmed its antitumor efficacy, including inhibiting tumor growth in xenograft models. Multi-omics analyses revealed that emodepside acts by inhibiting NAMPT, promoting TNBC cell apoptosis.

Clinical · Molecular biology · Bioinfo & AI

Identification and functional validation of lipid droplet-associated prognostic biomarkers in breast cancer via integrative multi-omics and machine learning approaches

Yao J, Liu Z, Zhang J, et al.

International journal of clinical oncology

This study identified and functionally validated lipid droplet (LD)-associated prognostic biomarkers in breast cancer through integrative multi-omics and machine learning. A prognostic model, built using the StepCox[both]+plsRcox algorithm, effectively stratified patients across molecular subtypes, outperforming traditional ER/PR/HER2 status. Key genes, SQLE and SOCS3, were identified with opposing roles: SQLE promoting adipogenesis and SOCS3 inhibiting it, influencing the tumor microenvironment and immune infiltration. Modulating these genes suppressed tumor growth and polarized macrophages towards an M1 phenotype, highlighting their potential as therapeutic targets.

Clinical · Bioinfo & AI

ProphDR: An Interpretable Deep Learning Model for Predicting Cancer Drug Response via Multi-Omics and Cross-Attention Mechanisms

Zeng Y, Ye Q, Wang J, et al.

Journal of chemical information and modeling

ProphDR is a novel interpretable deep learning model designed to predict cancer drug responses by integrating multi-omics data and drug structural information. The model employs hierarchical attention mechanisms, including a Criss-Cross Gene-level Multiomics Integration (CGMI) module and a cross-attention (CA) module to model drug-gene interactions. Evaluated on GDSC and CCLE datasets, ProphDR achieves state-of-the-art performance in predicting ln(IC50) values and classifying drug sensitivity. It also demonstrates strong generalizability, even for unseen drugs or cell lines, and generates biologically interpretable attention maps.

Clinical · Molecular biology · Bioinfo & AI

Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma

Su YL, Huang SY, Kuo CW, et al.

Journal for immunotherapy of cancer

This study investigates predictive biomarkers for immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma. Researchers found that ICI responders exhibited higher tumor mutational burden (TMB) and enriched mutations in genes such as PIK3CA. Functional in vitro and in vivo studies demonstrated that PIK3CA mutations enhance tumor immunogenicity by activating the IRF1-NLRC5-MHC-I axis, thereby improving antigen presentation and CD8+ T-cell cytotoxic response. These findings suggest that PIK3CA mutation could serve as a biomarker to predict ICI sensitivity and represents a novel immune-modulating mechanism.

Clinical · Molecular biology

Functional characterization of BRCA2 variants of uncertain significance identified in Korean breast cancer patients

Lim AR, Jung SP, Kim K, et al.

Breast cancer (Tokyo, Japan)

This study functionally characterized three BRCA2 variants of uncertain significance (VUS) identified in Korean breast cancer patients. Using BRCA2-knockout cell lines and various functional assays, researchers evaluated sensitivity to DNA-damaging agents and homologous recombination efficiency. The p.Asp1990Ala variant exhibited a pathogenic-like functional phenotype, characterized by increased sensitivity to cisplatin, ionizing radiation, and olaparib, along with impaired homologous recombination repair. In contrast, the p.Gly1224Asp and p.Cys1820Tyr variants were found to be functionally neutral. These findings highlight the heterogeneity of BRCA2 VUS and the importance of functional assays for their clinical interpretation.

Molecular biology · Bioinfo & AI

Comprehensive comparison of homologous recombination deficiency predictors in early-stage triple-negative breast cancer

Nacer DF, Veerla S, Sasiain I, et al.

Breast cancer research

This study comprehensively compared seven homologous recombination deficiency (HRD) prediction methods in 235 patients with early-stage triple-negative breast cancer. The methods included sequencing-based, copy number-based, functional, mRNA-based, and image-based approaches, with an exploratory comparison to the FDA-approved Myriad myChoice CDx assay. Results revealed substantial concordance among methods, alongside specific discordances attributed to data preprocessing and training strategies. Despite these variations, all methods demonstrated similar prognostic performance in patients treated with adjuvant chemotherapy. The study emphasizes the critical need for rigorous optimization of data processing workflows and threshold definitions to ensure consistency and reproducibility of HRD classifications.

Clinical

Risk prediction models for familial breast cancer

McGarrigle SA, Hanhauser YP, Mockler D, et al.

The Cochrane database of systematic reviews

This meta-analysis assessed the performance of breast cancer risk prediction models in women with a family history of the disease. The Gail (BCRAT) and BOADICEA models demonstrated good calibration, while Tyrer-Cuzick overpredicted and BRCAPRO underpredicted risk. Regarding discriminatory accuracy, no single model was clearly superior, with Tyrer-Cuzick version 8, BOADICEA, and BRCAPRO showing similar modest discrimination. The authors suggest that BOADICEA may be useful for patient management in familial breast cancer risk settings, despite limitations such as high risk of bias and study heterogeneity.

Clinical · Molecular biology

Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial

Lee KL, Yam C, Zhao L, et al.

Breast cancer research and treatment

This prospective study investigated the prevalence of non-BRCA germline pathogenic variants (PVs) and their impact on response to neoadjuvant therapy (NAT) in patients with triple-negative breast cancer (TNBC). Among 184 patients, 36% harbored PVs in pan-cancer susceptibility genes, including variants in 31 genes not previously found in other US cohorts. Patients received NAT with doxorubicin, cyclophosphamide, paclitaxel, and carboplatin, with or without immunotherapy or targeted therapy. Despite this high prevalence, the presence of these non-BRCA germline PVs was not associated with a significant difference in pathologic complete response (pCR) or radiologic response. The findings suggest the utility of multigene panels for screening but indicate that these variants are not predictive of NAT response in TNBC.

Clinical · Molecular biology · Bioinfo & AI

Assessing biomarkers for patients with breast cancer who are suited for adjuvant therapy

Rakha EA

Expert review of molecular diagnostics

This review examines established and emerging biomarkers for stratifying patients with early-stage breast cancer to optimize adjuvant systemic therapy. It highlights that while clinicopathological factors remain fundamental, decision-making is increasingly driven by precise biological markers. ER and HER2 status are crucial, and multigene assays refine recurrence risk and chemotherapy benefit in hormone receptor-positive cancers. Immune and DNA-repair biomarkers inform targeted therapies in HER2-positive and triple-negative subtypes, while mutation profiling of genes like ESR1, PIK3CA, AKT, MTOR, and PTEN guides targeted treatments. Emerging approaches, including liquid biopsy and artificial intelligence, offer dynamic insights but require prospective validation.

Clinical

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer

Weiner-Gorzel K, McSorley L, Walshe JM

Current treatment options in oncology

Improved survival rates for reproductive-age breast cancer patients highlight significant oncofertility challenges. Fertility preservation, gonadotoxicity, and pregnancy safety are key concerns requiring early and integrated management within the therapeutic plan. Prompt referral for fertility preservation is crucial, ensuring it does not compromise oncologic outcomes. Modern therapies such as PARP inhibitors, CDK4/6 inhibitors, HER2-monoclonal antibodies, and endocrine treatments raise specific questions due to a lack of prospective human fertility data. A precautionary approach is recommended, including effective contraception and adherence to washout periods.

Clinical · Molecular biology

Circulating tumor DNA in breast cancer: updates from SABCS 2025

Zhi I, Zou X, Sun M, et al.

Journal of hematology & oncology

Data from the 2025 San Antonio Breast Cancer Symposium highlight the expanding role of circulating tumor DNA (ctDNA) in breast cancer management. ctDNA is now being utilized to guide therapeutic decisions, particularly in advanced hormone receptor-positive breast cancer. The SERENA-6 trial demonstrated that ctDNA-detected ESR1 mutations enabled adaptation of endocrine therapy, leading to improved clinical outcomes. Furthermore, in early-stage disease, ctDNA identifies minimal residual disease (MRD) and patients at high risk of recurrence. These advancements position ctDNA as a crucial biomarker for precision oncology and dynamic treatment adaptation.

Clinical · Molecular biology

Navigating Treatment Decisions in Early-Stage Hormone Receptor-Positive Breast Cancer

Amir E, Kristoff T, Blaha C, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

This article discusses the increasing complexity of therapeutic decision-making for early-stage, hormone receptor-positive, HER2-negative breast cancer. It highlights the significance of advances in tumor biology, particularly genomic assays, in improving risk stratification and identifying patients most likely to benefit from chemotherapy. The review also explores current challenges and controversies, such as the use of genomic assays in premenopausal women with node-positive disease. Furthermore, it examines the emerging role of circulating tumor DNA as a prognostic and predictive biomarker.

Clinical

CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of Kaplan-Meier-reconstructed individual-level data

Veta Darkovski J, Michelon I, Gazzoni G, et al.

Breast cancer research

This meta-analysis investigated the efficacy of rechallenging with CDK4/6 inhibitors (CDK4/6i) after progression in patients with HR-positive, HER2-negative advanced/metastatic breast cancer. The study included 1396 patients from eight clinical trials, comparing CDK4/6i rechallenge plus endocrine therapy to endocrine therapy alone. Results indicated a significant improvement in median progression-free survival (PFS) of 5.8 months versus 3.7 months. A greater benefit was observed when switching to a different CDK4/6 inhibitor, particularly with abemaciclib, but no overall survival benefit was demonstrated.

Molecular biology

Comprehensive evidence for the pathogenicity of the BRCA2 c.7847C>T (p.Ser2616Phe) variant specific to the Japanese population

Yamazawa K, Ueki A, Kuga A, et al.

Journal of medical genetics

This nationwide Japanese study resolved the status of the BRCA2 c.7847C>T (p.Ser2616Phe) variant, which is specific to the Japanese population and was previously of uncertain significance. By integrating quantitative cosegregation analyses, robust functional evidence, and population frequency data, researchers accumulated strong evidence. The evaluation led to the reclassification of this variant as "Pathogenic" according to the ClinGen ENIGMA framework. This reclassification is crucial for ensuring eligible Japanese patients gain access to appropriate targeted therapies, such as PARP inhibitors.

Clinical

Evolving Treatment Paradigms in Hormone Receptor-Positive, Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer

Soliman S, Zitter R, Walker S, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

The treatment paradigm for hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) has significantly evolved from sequential therapies to more personalized strategies. CDK4/6 inhibitors combined with endocrine therapy remain the first-line standard of care, consistently improving progression-free survival and, for some agents, overall survival. The emergence of antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan is reshaping the therapeutic landscape, including for HER2-low and HER2-ultralow disease. Metastasis-directed therapy is also considered for oligometastatic or oligoprogressive disease, requiring nuanced decision-making. Overall management now integrates tumor biology, therapeutic advances, and patient-defined goals of care.

Molecular biology

Multimodal molecular profiling of invasive ductal carcinoma: High concordance of qPCR with FISH in HER2 assessment and exomic landscape of high-risk subtypes

Balar S, Joshi E, Rawal R, et al.

Pathology, research and practice

This study evaluates the efficacy of qPCR for HER2 status assessment in invasive ductal carcinoma of the breast, comparing it with IHC and FISH. Results demonstrate high concordance between qPCR and FISH, particularly in resolving equivocal IHC 2+ cases. Furthermore, exploratory genomic profiling via WES on high-risk subtypes (HER2 3+ and TNBC) revealed somatic mutations in key genes such as TP53, BRCA1, and MYCN, as well as AR expression in TNBC. These findings highlight qPCR’s potential as an accurate diagnostic tool and provide a foundation for future precision oncology strategies.

Molecular biology

Sensitive detection of somatic mutations in GC-rich cancer gene promoters

Qi M, Dave PS, Francis N, et al.

NAR cancer

Somatic mutations in GC-rich promoter regions are significant drivers of cancer, yet their detection is challenging due to poor sequencing coverage in these areas. This study introduces a hybrid capture assay optimized for over 3000 cancer gene promoters, enabling deep sequencing of these complex regions. This method facilitates the discovery of reliable point mutations, short insertions/deletions, copy number variants, and mutational signatures. The assay nominated candidate noncoding driver mutations in CDK4, SMAD3, and GATA3 in breast cancer, paving the way for future functional follow-up.

Molecular biology · Clinical

Whole genome sequencing of locally advanced and metastatic breast carcinoma unravels relevant molecular signatures and novel events

Kozan EN, Delgado-de la Mora J, Al Assaad M, et al.

Pathology, research and practice

This study performed whole genome and transcriptome sequencing on 50 tumor samples from 37 patients with locally advanced or metastatic breast cancer. It uncovered extensive genomic complexity, with triple-negative breast cancer (TNBC) showing the highest tumor mutational burden. Homologous recombination deficiency (HRD) was found in 27% of patients, frequently in BRCA1/2 wild-type cases due to deleterious structural variants in other repair genes. Therapeutically actionable alterations were identified in 84% of patients, including a novel ESR1::EP300 fusion potentially linked to endocrine resistance. These findings underscore the utility of whole-genome sequencing for characterizing metastatic disease and guiding therapies.

Clinical · Molecular biology · Bioinfo & AI

Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer

Papadopoulou E, Stathoulopoulou M, Matiatou M, et al.

Cancer genomics & proteomics

This study investigated the associations between clinicopathological characteristics and genetic alterations in breast cancer, focusing on how clinical and pathological variables influence the actionability of Next Generation Sequencing (NGS) data. Among 227 breast cancer patients, comprehensive genomic profiling revealed that a vast majority (95.6%) harbored at least one oncogenic alteration. Subtype-specific patterns were identified, with an enrichment of PIK3CA and ESR1 alterations in HR+/HER2- tumors, and a predominance of TP53 in triple-negative breast cancer. The study highlights that NGS-based genomic profiling identifies clinically actionable alterations in over half of breast cancer patients, particularly in the HR+/HER2- subtype, and supports its routine implementation, especially for metastatic HER2-negative breast cancer.